TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03196882
Drug: 40mg/day of iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
Study: NCT03196882
Drug: 80mg/day of iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
Study: NCT01369069
Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
Study: NCT04101227
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
Study: NCT03233633
Drug: Medical Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, high ratio CBD:THC
Study: NCT03351699
Drug: MK-4250
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-4250 tablets for oral administration
Study: NCT00689312
Drug: Enfalyte
Normalized name: Electrolytes Oral Solution [ENFAMIL ENFALYTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive one 250 ml dose.
Study: NCT00689312
Drug: Pediatric Electrolyte
Normalized name: Pediatric Electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive one 250 ml dose.
Study: NCT00689312
Drug: Pedialyte
Normalized name: Pedialyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive one 250 ml dose.
Study: NCT00190606
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03588715
Drug: 3BNC117 + 10-1074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
Study: NCT03071263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 packets/day starting dose, administered orally
Study: NCT03071263
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet/day starting dose, administered orally
Study: NCT03071081
Drug: TOP1288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TOP1288
Study: NCT03034486
Drug: D930, D565
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
Study: NCT03071081
Drug: Placebo to TOP1288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo to TOP1288
Study: NCT04211740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as granules and take orally once a week.
Study: NCT02735044
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting mealtime insulin analogs
Study: NCT00864123
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
Study: NCT01863823
Drug: Amoxicillin and Tetracyclines
Normalized name: tetracycline and nystatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
Study: NCT03841110
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT04228263
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg
Study: NCT03289208
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.
Study: NCT01601535
Drug: MLN8237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
Study: NCT03084796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT00647296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 2 tablets taken orally twice daily
Study: NCT00062712
Drug: Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00358475
Drug: GW685698
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04520607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-administered intra-articular injection of vehicle.
Study: NCT02997501
Drug: AZD9291 Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Study: NCT02214550
Drug: cyclic microgestin 1/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
Study: NCT02214550
Drug: continuous microgestin 1/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous OC use - Pills containing hormones will be taken every day for 1 year
Study: NCT04711213
Drug: Placebo Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension dose 1
Study: NCT04711213
Drug: Placebo Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension dose 2
Study: NCT03990051
Drug: Pro-ocular™ topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel for forehead dermal application
Study: NCT03990051
Drug: Placebo topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel for forehead dermal application
Study: NCT04918706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
Study: NCT04111328
Drug: intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
Study: NCT04111328
Drug: subcutaneous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
Study: NCT04111328
Drug: intravenous sufentanil and dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
Study: NCT04111328
Drug: subcutaneous sufentanil and dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
Study: NCT01080625
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
Study: NCT02171806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01652417
Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone bolus IV 15 mg/kg/d for 3 days.
Study: NCT03433586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
Study: NCT01034514
Drug: TECHNETIUM TC 99M MAA
Normalized name: TECHNETIUM TC 99M MAA UNIT DOSE INJ,SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mCi; iv
Study: NCT00901901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching erlotinib placebo 150 mg once daily
Study: NCT00382044
Drug: Eprex; Neorecormon; Aranesp
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01837472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
Study: NCT00757081
Drug: phosphatidylcholine and deoxycholate
Normalized name: deoxycholate
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
Study: NCT03373708
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2
Study: NCT00542035
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1, dose 2
Study: NCT00542035
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1, dose 2
Study: NCT00542035
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1
Study: NCT00542035
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 2
Study: NCT01673555
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863
Study: NCT01673555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00282971
Drug: Inhaled Insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of inhaled insulin to pre-existing oral diabetes therapy.
Study: NCT01319981
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
Study: NCT01319981
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
Study: NCT01319981
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
Study: NCT01662167
Drug: Single
Normalized name: Singlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
Study: NCT02386020
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After SRP, placebo gel was delivered subgingivally into periodontal pockets.
Study: NCT02458742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
Study: NCT00282763
Drug: MK0686
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00879060
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 50mg daily
Study: NCT00879060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive placebo pill daily
Study: NCT01756833
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg po bid
Study: NCT01756833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule identical to the doxycycline capsule
Study: NCT00443040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
Study: NCT03778242
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo ampoules to TA in 100 ml saline by slow infusion
Study: NCT04346095
Drug: Oral Sedatives with or Without Analgesia
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Study: NCT04346095
Drug: Intravenous Sedatives with or Without Analgesia
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
Study: NCT04674293
Drug: Revelisa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for patients with ischemic stroke
Study: NCT01432665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT03482635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT01432665
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT04541303
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00152841
Drug: Iron supplement 300-600 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01441843
Drug: NaCl 0.9% (Sodium Chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
Study: NCT00307892
Drug: Traumeel S: intra-operative irrigation + oral ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: homeopathic remedy
Study: NCT00307892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo remedy
Study: NCT03858686
Drug: Placebo FP-025 capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study: NCT01889667
Drug: ORMD-0801 Dose # 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Insulin Formulation
Study: NCT01889667
Drug: ORMD-0801 Dose # 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Insulin Formulation
Study: NCT01889667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil Capsules
Study: NCT03169244
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be initiated on Day 1 and continue throughout the course of the study.
Study: NCT04458636
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT04151940
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care chemotherapy
Study: NCT00961155
Drug: cyklezonid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mcg once daily
Study: NCT00961155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone placebo twice daily, montelukast placebo once daily
Study: NCT02608944
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
Study: NCT01469221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly multi-instillation of matching placebo in 40mL
Study: NCT03106571
Drug: Pomaglumetad methionil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily
Study: NCT03106571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-4 tablets twice daily
Study: NCT03547778
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
Study: NCT02016196
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
Study: NCT04297865
Drug: A dose as CJ-15314
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose as CJ-15314, 1 capsule
Study: NCT04297865
Drug: B dose as CJ-15314
Approvals — FDA: no, EMA: no, PMDA: no
Description: B dose as CJ-15314, 1 capsule
Study: NCT04297865
Drug: C dose as CJ-15314
Approvals — FDA: no, EMA: no, PMDA: no
Description: C dose as CJ-15314, 1 capsule
Study: NCT04297865
Drug: D dose as CJ-15314
Approvals — FDA: no, EMA: no, PMDA: no
Description: D dose as CJ-15314, 2 capsules
Study: NCT04297865
Drug: E dose as CJ-15314
Approvals — FDA: no, EMA: no, PMDA: no
Description: E dose as CJ-15314, 1 capsule
Study: NCT04297865
Drug: F dose as CJ-15314
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F dose as CJ-15314, 2 capsules
Study: NCT04297865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 capsule
Study: NCT04297865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules
Study: NCT00566735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg, 2 times a day
Study: NCT03382717
Drug: Loceryl 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 application per week during 6 months
Study: NCT01952132
Drug: OMS643762
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415829
Drug: capecitabine plus oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
Study: NCT01952132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02444429
Drug: Corticosteroid boluses Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered
Study: NCT01614522
Drug: ASLAN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN001 500mg BID
Study: NCT03990285
Drug: Axumin, Intravenous Solution
Normalized name: Axumin, intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
Study: NCT01792934
Drug: XELOX regimen according to standard procedures
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01792934
Drug: FOLFOX regimen according to standard procedures
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04339348
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
Study: NCT00964730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered three times a day over 9 days and a single dose administered on Day 10
Study: NCT03573518
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00069901
Drug: CT-2103 (poly(L)glutamate-paclitaxel)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468806
Drug: GSK598809, using [11C]-(+)-PHNO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00891332
Drug: S-1 plus LV (The combination therapy of S-1 and Leucovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Study: NCT02213744
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01723241
Drug: XAF5, concentration A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01723241
Drug: XAF5, concentration B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01723241
Drug: XAF5, concentration C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01723241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02530827
Drug: use of lipid-lowering drugs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Study: NCT00268476
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00268476
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00268476
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00268476
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00268476
Drug: Transdermal Oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184795
Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet per day for 24 weeks
Study: NCT01323933
Drug: AB0024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of drug
Study: NCT02268760
Drug: BILN 2061 ZW single rising doses
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00184795
Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet per day for 24 weeks
Study: NCT00184795
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 24 weeks
Study: NCT01527123
Drug: GSK2585823
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLDM1%/BPO3%
Study: NCT02567656
Drug: RP6530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet starting at 200 mg
Study: NCT04146129
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of normal saline
Study: NCT01822249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no